{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-008444","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.692048+00:00","generated_at":"2026-05-26T02:56:19.017519+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel reports record Q4 gross margin 78%, FY2024 revenue up 20% to $237M, net income positive","bullets":["Full-year 2024 revenue $237.2M (+20% YoY); MACI $197.3M (+20%), Burn Care $39.9M (+22%).","Q4 GAAP net income $19.8M ($0.38 diluted EPS) vs $13.0M YoY; adjusted EBITDA margin 40%.","FY2024 adjusted EBITDA $53.4M (23% margin), up 58% YoY; operating cash flow $58.2M.","2025 guidance: revenue growth 20-23%, gross margin 73-74%, adj. EBITDA margin 25-26%.","MACI Arthro launch traction: ~250 surgeons trained; NexoBrid orders +42% QoQ; new facility on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-008444","json":"https://secwatch.observer/filing/0001628280-25-008444.json","markdown":"https://secwatch.observer/filing/0001628280-25-008444.md","text":"https://secwatch.observer/filing/0001628280-25-008444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828025008444/0001628280-25-008444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828025008444/vcel-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:56:19.017519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}